

(Continued from page 22N)

The NRPE plan calls for the continuous monitoring of radionuclide needs of researchers and clinicians and the establishment of an education program to ensure that the next generation of nuclear and molecular imaging professionals are trained and available to support the nation's critical needs. The plan also asks for upgrading the capability of MURR and other existing facilities that produce radionuclides and stable isotopes.

Briefly, here are the proposal's 5 specific goals, its timeline, and the requested appropriations. In fiscal year 2006, \$6.3 million would be needed for upgrading MURR from 10 to 20 MW and to support the work of a select committee, which will be formed to define the optimal operating characteristics for a cyclotron production facility. The next year, approximately \$29–\$39 million would be used to begin installation of a new cyclotron, which would be completed by 2010.

For fiscal years 2008–2010, \$3 million would be used each year to fund research and development of small-energy cyclotron targets, to research radionuclide production capability, and to pay for operating costs of the new cyclotron. In fiscal years 2010–2015, \$4 million will be used each year for research and development funding for Oak Ridge National Laboratory to upgrade processing hot cells for a stable supply of alpha-emitting radionuclides for therapeutic applications and to produce alpha emitters for therapeutic uses. In fiscal year 2016, approximately \$5 million would fund an isotope separator to produce en-

riched stable isotopes that are required as target material for production of both reactor-produced and cyclotron-produced radionuclides.

Radionuclides are part of the foundation supporting today's applied molecular/nuclear technology. The very duality of purpose of molecular/nuclear medicine—offering both noninvasive diagnostic methodology and a powerful therapeutic modality—drives the exploration and development of new radiopharmaceuticals. Radiopharmaceutical research leads to a better understanding and improved or early diagnosis of human diseases and to the development of effective treatments and the monitoring of the effectiveness of existing ones. For these reasons, SNM is committed to gaining support for this program and to promoting it at the federal level.

Many thanks go to the individuals who served on the NRPE Task Force, including Michael J. Welch, PhD, chair; Richard C. Reba, MD; Barbara Y. Croft, PhD; David Hill, PhD; Robert F. Carretta, MD; Alan R. Ketrting, PhD; Peter T. Kirchner, MD; Edward B. Silberstein, MD; Wynn A. Volkert, PhD; D. Scott Wilbur, PhD; Iain Trevena, PhD; and Roy Brown, PhD. SNM also thanks Martin Brechbiel, PhD, Suresh Srivastava, PhD, and John Pantaleo for their technical contributions and Daniel Sullivan, MD, for his support. Our thanks also go to the leadership of organizations who thoughtfully supported this program of national importance.

Mathew L. Thakur, PhD
President, SNM

Erratum March 2005 Newsline

The subhead, "Goal: Membership in SNM Will Be Viewed as Essential by All With an Interest in the Field of Nuclear Medicine and Molecular Imaging," was inadvertently omitted in the SNM Leadership Update. A corrected version appears in the Newsline section of the SNM journals Web site at <http://jnm.snmjournals.org/cgi/reprint/46/24N>.